B+
Bull case
25%
Probability
Target price
$315.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CRL
Charles River Laboratories InternationalCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 print appears better than the packet’s pre-release Zacks estimates of $970.8 million revenue and $2.72 non-GAAP EPS, while the company raised full-year guidance and reported improving DSA demand and a multiyear-high book-to-bill [#PR-EARNINGS-2026-07-30] [#SEC-8K-2026-08-05].
Posture
Mixed
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-25.
What can break
Divestiture-related losses and portfolio restructuring may continue to distort GAAP earnings and execution.
Momentum
97
Value
58
Sentiment
34
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $282.00 · Bull $315.00 · Bear $220.00Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $326.29
Why
Momentum97 · Δ7d +0.1
Value58 · Δ7d -0.7
Sentiment34 · Δ7d -13.0
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-25.
- • Value remains the lead driver in the composite, 7D delta -0.7.
Contradictions & invalidation
- • Divestiture-related losses and portfolio restructuring may continue to distort GAAP earnings and execution.
- • Higher DSA study-related direct costs and corporate expenses could delay margin recovery.
- • RMS remains weak, DSA costs compressed non-GAAP margins, and the GAAP result included a $63.7 million divestiture-related loss.
Catalyst clock
2026-08-05
Q2 results and FY2026 guidance raise
Lead driver: Value · See fundamentals
Momentum
97
8% active weight
Current posture
7d trendSoftening
Δ7d
+0.1
Δ21d
+2.2
Value
58
47% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
-1.5
Sentiment
34
45% active weight
Current posture
7d trendSoftening
Δ7d
-13.0
Δ21d
-23.3
Why this grade
Composite grade C. Momentum 96.8 / Value 57.9 / Sentiment 34.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$282.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$220.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$16.49B
Beta
1.63
Shares Out
47.74M
P/E (TTM) · Derived
-118.6
P/S (TTM)
2.55
P/FCF (TTM)
18.86
Rev YoY
-2.7%
EPS YoY
-102.9%
Gross Margin
+32.6%
Op Margin
+13.5%
Net Debt
$2.42B
Current Ratio
1.35
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data